



PositiveID Corporation's iglucose Mobile Health Solution Makes Significant Progress With Active Customer Deployments

iglucose Mobile Health Solution for Diabetes Management Undergoing Trials With Leading Health Insurer, Consumer Healthcare Products Company and International Telecom Provider

DELRAY BEACH, Fla., April 16, 2012 (GLOBE NEWSWIRE) -- PositiveID Corporation ("PositiveID" or "Company") (OTCBB:PSID), an emerging growth company and developer of advanced technologies for diabetes management as well as sophisticated airborne bio-threat detection systems for America's homeland defense, today announced significant progress with the initial deployment of its FDA-cleared iglucose™ mobile health system for diabetes management. The iglucose System is currently being trialed by a leading health insurer, a large consumer healthcare products company and an international telecommunications provider. The Company also recently announced the use of iglucose in a trial with a leading global pharmaceutical company.

PositiveID's FDA-cleared [iglucose](#) System is a convenient and easy-to-use wireless solution designed to empower individuals with diabetes to become more engaged in the self-management of their condition. iglucose seamlessly communicates blood glucose data from glucometers to the iglucose diabetes management portal, where reports are generated and can be shared with family members and healthcare professionals, making it possible to improve care in a cost-effective manner. The iglucose system communicates according to the user's preferences via online access, email, fax or SMS text. iglucose eliminates the burden of keeping logbooks and enables individuals with diabetes to proactively take control of their glucose levels and treatment regimens. iglucose does not require the use of a cell phone or a wireless plan.

"Many large organizations are currently trialing iglucose, from one of the largest health insurers in the U.S., to one of the largest consumer healthcare products companies in the world," stated William J. Caragol, PositiveID's Chairman and CEO. "We are providing this progress report following our announcement last week that we made iglucose available for pre-order for consumers. We received a very positive response and therefore want to update the investor community as well as those with diabetes about our next steps."

The iglucose system collects and transmits stored data from a variety of FDA-cleared blood glucose meters such as Johnson & Johnson LifeScan®, Abbott FreeStyle®, Bayer Contour®, and Nipro Diagnostic™ True™ monitoring systems to a secure database via wireless cellular technology. PositiveID is continually adding to this list of supported glucose meters. For more information on iglucose, visit www.iglucose.com.

About PositiveID Corporation

PositiveID Corporation is an emerging growth company and developer of advanced technologies for diabetes management and rapid medical testing, as well as airborne bio-threat detection systems for America's homeland defense. Its wholly-owned subsidiary, Microfluidic Systems, or MFS, is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment.

For more information on PositiveID, please visit www.PositiveIDCorp.com.

The PositiveID Corporation logo is available at <http://www.globenewswire.com/newsroom/prs/?pkgid=7717>

Statements about PositiveID's future expectations, including the likelihood that the Company is making significant progress with the initial deployment of its FDA-cleared iglucose™ mobile health system for diabetes management; the likelihood that iglucose is a convenient and easy-to-use wireless solution designed to empower individuals with diabetes to become more engaged in the self-management of their condition; the likelihood that iglucose makes it possible to improve care in a cost-effective manner; the likelihood that iglucose eliminates the burden of keeping logbooks and enables individuals with diabetes to proactively take control of their glucose levels and treatment regimens; the likelihood that the Company is continually adding to its list of supported glucose meters; and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include PositiveID's ability to successfully commercialize iglucose, as well as certain other

risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 28, 2012, and 10-Qs filed on May 13, 2011, August 15, 2011, and November 14, 2011, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

CONTACT: PositiveID Corporation

Allison Tomek

561-805-8000

atomek@positiveidcorp.com

Trilogy Capital Partners, Inc.

Darren Minton, President

Toll-free: 800-592-6067

info@trilogy-capital.com



Source: PositiveID Corporation

News Provided by Acquire Media